Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer's disease mice

Biomaterials

Volumn 80, Issue , 2016, Pages 33-45

  Liu, Yang ^a   An, Sai ^a   Li, Jianfeng ^a   Kuang, Yuyang ^a   He, Xi ^a   Guo, Yubo ^a   Ma, Haojun ^a   Zhang, Yu ^a   Ji, Bin ^b   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Alzheimer's disease; A ; Brain targeted delivery; Gene therapy; Non coding RNA; Tau fibril

Indexed keywords

AMINO ACIDS; DISEASE CONTROL; GENE THERAPY; GENES; MAMMALS; NEURODEGENERATIVE DISEASES; PEPTIDES; RNA;

ALZHEIMER'S DISEASE; MULTI-FUNCTIONAL NANOCARRIERS; MULTI-FUNCTIONAL NANOPARTICLES; MULTIFUNCTIONAL NANOCARRIER; NON-CODING RNAS; SYSTEMIC ADMINISTRATION; TARGETED DELIVERY; TAU-FIBRIL;

DISEASES;

AMYLOID BETA PROTEIN; BETA SECRETASE 1; GLYCOPROTEIN; MONOMER; NANOCARRIER; NICOTINIC RECEPTOR; PEGYLATED DENDIGRAFT POLYLYSINE; PLASMID DNA; POLYLYSINE; RABIES VIRUS GLYCOPROTEIN 29; SHORT HAIRPIN RNA; THIOL GROUP; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VIRUS PROTEIN; DRUG CARRIER; MACROGOL DERIVATIVE; NANOPARTICLE; PEPTIDE; POLYLYSINE-GRAFT-(POLY(ETHYLENE GLYCOL));

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG DELIVERY SYSTEM; ELECTRIC RESISTANCE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE SILENCING; HIPPOCAMPUS; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LEARNING; MORRIS WATER MAZE TEST; MOUSE; MTT ASSAY; NEUROFIBRILLARY TANGLE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TRANSCYTOSIS; TRANSENDOTHELIAL ELECTRICAL RESISTANCE; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CHEMISTRY; DRUG EFFECTS; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHARMACOKINETICS; PLAQUE, AMYLOID; PLASMID; THERAPEUTIC USE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PEPTIDES; ANIMALS; BASE SEQUENCE; BRAIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NANOPARTICLES; PEPTIDES; PLAQUE, AMYLOID; PLASMIDS; POLYETHYLENE GLYCOLS; POLYLYSINE; RNA, UNTRANSLATED;

EID: 84951851548     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.11.060     Document Type: Article

References (66)

1. Sun T., Zhang Y.S., Pang B., Hyun D.C., Yang M., Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 2014, 53:12320-12364.
2. Jiang W., Kim B.Y., Rutka J.T., Chan W.C. Advances and challenges of nanotechnology-based drug delivery systems. Expert Opin. Drug Deliv. 2007, 4:621-633.
3. Wang Y., Miao L., Satterlee A., Huang L. Delivery of oligonucleotides with lipid nanoparticles. Adv. Drug Deliv. Rev. 2015, 68-80.
4. Gu X., Chen H., Gao X. Nanotherapeutic strategies for the treatment of Alzheimer's disease. Ther. Deliv. 2015, 6:177-195.
5. Ittner L.M., Gotz J. Amyloid-beta and tau-a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
6. Ballatore C., Lee V.M., Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 2007, 8:663-672.
7. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 2011, 10:698-712.
8. Pardridge W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 12:54-61.
9. Pahuja R., Seth K., Shukla A., Shukla R.K., Bhatnagar P., Chauhan L.K., Saxena P.N., Arun J., Chaudhari B.P., Patel D.K., Singh S.P., Shukla R., Khanna V.K., Kumar P., Chaturvedi R.K., Gupta K.C. Trans-blood brain barrier delivery of dopamine loaded nanoparticles reverses functional deficits in Parkinsonian rats. ACS Nano 2015, 4850-4871.
10. Angelov B., Angelova A., Drechsler M., Garamus V.M., Mutafchieva R., Lesieur S. Identification of large channels in cationic PEGylated cubosome nanoparticles by synchrotron radiation SAXS and Cryo-TEM imaging. Soft Matter 2015, 11:3686-3692.
11. Angelova A., Angelov B., Drechsler M., Lesieur S. Neurotrophin delivery using nanotechnology. Drug Discov. Today 2013, 18:1263-1271.
12. Angelov B., Angelova A., Filippov S.K., Narayanan T., Drechsler M., Stepanek P., Couvreur P., Lesieur S. DNA/fusogenic lipid nanocarrier assembly: millisecond structural dynamics. J. Phys. Chem. Lett. 2013, 4:1959-1964.
13. Angelov B., Angelova A., Filippov S.K., Drechsler M., Stepanek P., Lesieur S. Multicompartment lipid cubic nanoparticles with high protein upload: millisecond dynamics of formation. ACS Nano 2014, 8:5216-5226.
14. Angelova A., Angelov B., Drechsler M., Garamus V.M., Lesieur S. Protein entrapment in PEGylated lipid nanoparticles. Int. J. Pharm. 2013, 454:625-632.
15. Geral C., Angelova A., Lesieur S. From molecular to nanotechnology strategies for delivery of neurotrophins: emphasis on brain-derived neurotrophic factor (BDNF). Pharmaceutics 2013, 5:127-167.
16. Angelova A., Angelov B., Mutafchieva R., Lesieur S., Couvreur P. Self-assembled multicompartment liquid crystalline lipid carriers for protein, peptide, and nucleic acid drug delivery. Acc. Chem. Res. 2011, 44:147-156.
17. Miao L., Guo S., Zhang J., Kim W.Y., Huang L. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer. Adv. Funct. Mater. 2014, 24:6601-6611.
18. Guo S., Lin C.M., Xu Z., Miao L., Wang Y., Huang L. Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 2014, 8:4996-5009.
19. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
20. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Gotz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
21. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
22. Choy R.W., Cheng Z., Schekman R. Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid beta (Abeta) production in the trans-golgi network. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E2077-E2082.
23. O'Brien R.J., Wong P.C. Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 2011, 34:185-204.
24. Lee E.B., Zhang B., Liu K., Greenbaum E.A., Doms R.W., Trojanowski J.Q., Lee V.M. BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J. Cell Biol. 2005, 168:291-302.
25. Jiang Y., Mullaney K.A., Peterhoff C.M., Che S., Schmidt S.D., Boyer-Boiteau A., Ginsberg S.D., Cataldo A.M., Mathews P.M., Nixon R.A. Alzheimer's-related endosome dysfunction in down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1630-1635.
26. Hussain I., Hawkins J., Harrison D., Hille C., Wayne G., Cutler L., Buck T., Walter D., Demont E., Howes C., Naylor A., Jeffrey P., Gonzalez M.I., Dingwall C., Michel A., Redshaw S., Davis J.B. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J. Neurochem. 2007, 100:802-809.
27. Singer O., Marr R.A., Rockenstein E., Crews L., Coufal N.G., Gage F.H., Verma I.M., Masliah E. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat. Neurosci. 2005, 8:1343-1349.
28. Evin G., Barakat A., Masters C.L. BACE: therapeutic target and potential biomarker for Alzheimer's disease. Int. J. Biochem. Cell Biol. 2010, 42:1923-1926.
29. Ma H., Lesne S., Kotilinek L., Steidl-Nichols J.V., Sherman M., Younkin L., Younkin S., Forster C., Sergeant N., Delacourte A., Vassar R., Citron M., Kofuji P., Boland L.M., Ashe K.H. Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:8167-8172.
30. Laird F.M., Cai H., Savonenko A.V., Farah M.H., He K., Melnikova T., Wen H., Chiang H.C., Xu G., Koliatsos V.E., Borchelt D.R., Price D.L., Lee H.K., Wong P.C. BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J. Neurosci. 2005, 25:11693-11709.
31. Faghihi M.A., Modarresi F., Khalil A.M., Wood D.E., Sahagan B.G., Morgan T.E., Finch C.E., St Laurent G., Kenny P.J., Wahlestedt C. Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 2008, 14:723-730.
32. Gao Y., Chen L., Zhang Z., Chen Y., Li Y. Reversal of multidrug resistance by reduction-sensitive linear cationic click polymer/iMDR1-pDNA complex nanoparticles. Biomaterials 2011, 32:1738-1747.
33. Brunden K.R., Trojanowski J.Q., Lee V.M. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat. Rev. Drug Discov. 2009, 8:783-793.
34. De Felice F.G., Wu D., Lambert M.P., Fernandez S.J., Velasco P.T., Lacor P.N., Bigio E.H., Jerecic J., Acton P.J., Shughrue P.J., Chen-Dodson E., Kinney G.G., Klein W.L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging 2008, 29:1334-1347.
35. Sievers S.A., Karanicolas J., Chang H.W., Zhao A., Jiang L., Zirafi O., Stevens J.T., Münch J., Baker D., Eisenberg D. Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation. Nature 2011, 475:96-100.
36. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., Lee S.K., Shankar P., Manjunath N. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
37. Liu Y., Huang R., Han L., Ke W., Shao K., Ye L., Lou J., Jiang C. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 2009, 30:4195-4202.
38. Cottet H., Martin M., Papillaud A., Souaid E., Collet H., Commeyras A. Determination of dendrigraft poly-L-lysine diffusion coefficients by taylor dispersion analysis. Biomacromolecules 2007, 8:3235-3243.
39. Tsogas I., Theodossiou T., Sideratou Z., Paleos C.M., Collet H., Rossi J.C., Romestand B., Commeyras A. Interaction and transport of poly(L-lysine) dendrigrafts through liposomal and cellular membranes: the role of generation and surface functionalization. Biomacromolecules 2007, 8:3263-3270.
40. Xie Y., Ye L., Zhang X., Cui W., Lou J., Nagai T., Hou X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J. Control Release 2005, 105:106-119.
41. Ridley D.L., Pakkanen J., Wonnacott S. Effects of chronic drug treatments on increases in intracellular calcium mediated by nicotinic acetylcholine receptors in SH-SY5Y cells. Br. J. Pharmacol. 2002, 135:1051-1059.
42. Lukas R.J., Norman S.A., Lucero L. Characterization of nicotinic acetylcholine receptors expressed by cells of the SH-SY5Y human neuroblastoma clonal line. Mol. Cell Neurosci. 1993, 4:1-12.
43. Kuang Y., An S., Guo Y., Huang S., Shao K., Liu Y., Li J., Ma H., Jiang C. T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int. J. Pharm. 2013, 454:11-20.
44. Liu T., Oukacine F., Collet H., Commeyras A., Vial L., Cottet H. Monitoring surface functionalization of dendrigraft poly-L-lysines via click chemistry by capillary electrophoresis and Taylor dispersion analysis. J. Chromatogr. A 2013, 1273:111-116.
45. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65:8984-8992.
46. Davis M.E., Chen Z.G., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 2008, 7:771-782.
47. Oyewumi M.O., Yokel R.A., Jay M., Coakley T., Mumper R.J. Comparison of cell uptake, biodistribution and tumor retention of folate-coated and PEG-coated gadolinium nanoparticles in tumor-bearing mice. J. Control Release 2004, 95:613-626.
48. Kim S.H., Jeong J.H., Chun K.W., Park T.G. Target-specific cellular uptake of PLGA nanoparticles coated with poly(L-lysine)-poly(ethylene glycol)-folate conjugate. Langmuir 2005, 21:8852-8857.
49. Li S.D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J. Control Release 2010, 145:178-181.
50. Chong P., Sia C., Tripet B., James O., Klein M. Comparative immunological properties of enantiomeric peptides. Lett. Pept. Sci. 1996, 3:99-106.
51. Liu L., Xu K., Wang H., Tan P.K., Fan W., Venkatraman S.S., Li L., Yang Y.Y. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 2009, 4:457-463.
52. Pokharkar V., Dhar S., Bhumkar D., Mali V., Bodhankar S., Prasad B.L. Acute and subacute toxicity studies of chitosan reduced gold nanoparticles: a novel carrier for therapeutic agents. J. Biomed. Nanotechnol. 2009, 5:233-239.
53. Hou C.H., Hou S.M., Hsueh Y.S., Lin J., Wu H.C., Lin F.H. The in vivo performance of biomagnetic hydroxyapatite nanoparticles in cancer hyperthermia therapy. Biomaterials 2009, 30:3956-3960.
54. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
55. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
56. Kurt M.A., Davies D.C., Kidd M., Duff K., Howlett D.R. Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiol. Dis. 2003, 14:89-97.
57. Shi J.Q., Shen W., Chen J., Wang B.R., Zhong L.L., Zhu Y.W., Zhu H.Q., Zhang Q.Q., Zhang Y.D., Xu J. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011, 1368:239-247.
58. Yu Y., He J., Zhang Y., Luo H., Zhu S., Yang Y., Zhao T., Wu J., Huang Y., Kong J., Tan Q., Li X.M. Increased hippocampal neurogenesis in the progressive stage of Alzheimer's disease phenotype in an APP/PS1 double transgenic mouse model. Hippocampus 2009, 19:1247-1253.
59. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., Brunden K.R., Wilson D.A., Landreth G.E. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
60. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
61. Huang R., Liu S., Shao K., Han L., Ke W., Liu Y., Li J., Huang S., Jiang C. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene delivery vectors. Nanotechnology 2010, 21:265101.
62. Liu Y., Li J., Shao K., Huang R., Ye L., Lou J., Jiang C. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials 2010, 31:5246-5257.
63. Sutherland R.J., McDonald R.J. Hippocampus, amygdala, and memory deficits in rats. Behav. Brain Res. 1990, 37:57-79.
64. Ashe K.H. Learning and memory in transgenic mice modeling Alzheimer's disease. Learn Mem. 2001, 8:301-308.
65. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
66. Pistell P.J., Zhu M., Ingram D.K. Acquisition of conditioned taste aversion is impaired in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease. Neuroscience 2008, 152:594-600.